NEW YORK – Remepy, a developer of Hybrid Drugs, has closed a $36 million Series A financing round led by O.G. Venture Partners and M Ventures, the corporate strategic venture arm of Merck KGaA, Darmstadt, Germany, with participation of existing and new investors including NFX, Vine Ventures, Qumra Capital, TechAviv, 97212 Ventures, Fresh Fund, PsyMed Ventures, Tadmor Group, Key1 Capital, and IT-Farm Corp.
The proceeds will be used to accelerate the Company’s pharmaceutical co-development partnerships and expansion of its Hybrid Drug pipeline and platform and fund the global Phase III clinical development of Hybridopa, Remepy’s lead program for Parkinson’s disease that will commence in Q4 2026. This funding brings the total capital raised by the Company to $62 million.
Remepy partners with leading pharmaceutical companies to develop Hybrid Drugs, a new class of drugs that combine prescription medicines with personalized, AI-driven therapeutic apps. Hybrid Drugs integrate pharmacology with adaptive physical, cognitive, and behavioral interventions into a single treatment, enabling scalable, multidisciplinary care through the standard prescription model. Beyond improving patient outcomes, the platform creates significant strategic value for pharmaceutical companies by generating new intellectual property, enabling lifecycle management, differentiating existing and future drugs, and potentially increasing clinical trial success through personalized integrative treatment.
Supported by emerging FDA frameworks for drug-software combination products and regulatory alignment, the Hybrid Drug model is rapidly gaining industry momentum. The Company recently announced a strategic collaboration with Merck KGaA, Darmstadt, Germany, to develop Hybrid Drugs across multiple indications, beginning with rare tumors.
Hybridopa, Remepy’s Hybrid Drug program for Parkinson’s disease, has generated encouraging Phase IIa clinical results demonstrating improvements in both motor and non-motor symptoms, supported by peer-reviewed publications highlighting the biological mechanisms underlying the Hybrid Drug clinical effect. The Company is now preparing the program for global Phase III development, expected to commence in Q4, 2026. Hybridopa is investigational and is not approved by the FDA.
Michal Tsur, PhD, and Or Shoval, Co-CEOs of Remepy, “We believe medicine is entering a new era, where every breakthrough drug will be paired with personalized intelligence to maximize its impact for every patient. Over the past year, we’ve demonstrated that this vision is achievable through clinical validation, peer-reviewed science, regulatory alignment, and partnerships with leading pharmaceutical companies. This financing allows us to advance Phase III of Hybridopa for Parkinson’s disease, and expand the Hybrid Drug model across multiple therapeutic areas.”
Ziv Kop, Managing Partner at O.G. Venture Partners (Israel), “We’re excited to lead Remepy’s Series A and support an exceptional team pioneering a new category of medicine. By bringing together biotechnology, AI, and digital health, Remepy is redefining how medicines are developed and delivered. With compelling clinical data, growing regulatory momentum, and strong validation from leading pharmaceutical partners, we believe Hybrid Drugs have the potential to transform patient care – and we’re proud to support Remepy in its next phase of growth.”
Dr. Eyal Ben Ami, Scientific Lead at M Ventures, “Remepy’s pioneering Hybrid Drugs approach reflects the growing importance and applicability of integrating AI into the delivery of health and physical medicines. Our investment from M Ventures is intended to further enable the company, underscoring our belief that this new class of medicine – that combines innovative therapeutics with AI-driven, patient-centered care – has the potential to redefine medicine. We look forward to advancing it across multiple drug classes and disease areas.”
